Skip to content

    Vinati Organics Limited

    VINATIORGAGood
    Chemicals·17 May 2024
    Management Summary

    Vinati Organics reported a strong sequential recovery in Q4 FY24, signaling the end of the global destocking cycle that hampered FY24 annual performance. While full-year profits and revenues were down compared to FY23, the company is seeing robust demand recovery in its core ATBS segment and high utilization in Butyl Phenols. Management is pivoting towards growth with a significant capex plan and a target of 20% revenue CAGR over the next three years.

    Highlights

    7
    • Q4 FY24 Revenue reached ₹560 crores, a sequential increase of 23% from Q3 FY24.

    • EBITDA for the quarter stood at ₹160 crores, up 29% QoQ, with PAT at ₹104 crores, up 30% QoQ.

    • FY24 annual revenue declined 9% YoY to ₹1,930 crores, while PAT fell 23% to ₹323 crores due to earlier destocking.

    • ATBS global market share remains stable at 60-65%; sales have normalized following the end of the destocking cycle.

    • Butyl phenols capacity utilization reached nearly 100% in Q4, contributing ₹300 crores to FY24 revenue.

    • Management guided for a 20% revenue CAGR over the next 3 years, driven by new products and capacity expansions.

    • Total capex for FY25 is planned at ₹550 crores, including ATBS expansion and VOPL subsidiary projects.

    Concerns

    1
    • Chinese Competition in Antioxidants

    What Changed1

    vs Q1 FY25

    Risks discussed4 → 3 (-1)
    Key financials

    Metrics

    6

    Periods

    2

    Headline

    3
    • Total Income
      ₹560 Cr
      QoQ+23%
    • EBITDA
      ₹160 Cr
      QoQ+29.0%
    • PAT
      ₹104 Cr
      QoQ+30%

    FY24

    3
    • Revenue
      ₹1,930 Cr
      YoY-9%
    • EBITDA
      ₹509 Cr
      YoY-18%
    • PAT
      ₹323 Cr
      YoY-23%

    Segment breakdown

    RevenueCapacity Utilization
    ATBS
    Butyl Phenols₹300 Cr100%
    Antioxidants₹130 Cr25%
    Heatmap· 2 shared metrics

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Revenue CAGR
    20%
    High
    Revenue
    VOPL Revenue
    ₹280-300 crores
    Medium
    Margin
    EBITDA Margin
    26%
    Medium
    Capex
    Total Capex
    ₹550 crores
    High
    Capacity
    ATBS Expansion Completion
    December or January
    Medium

    Risks & concerns

    5
    RiskSeverity

    Chinese Competition in Antioxidants

    Management noted significant price erosion in the AO segment due to Chinese supply and slow global plastic markets.Both acknowledged

    high

    Equipment Delivery Delays

    Delivery constraints for equipment ordered from Europe are delaying the ATBS expansion commissioning to late FY25.Management acknowledged

    medium

    Raw Material Price Volatility

    Revenue potential for products like Butyl Phenol is sensitive to fluctuations in input raw material prices like Isobutyl Benzene (IB).Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific product-wise margin breakups
    • Detailed volume vs realization split for IBB

    Q&A highlights

    3

    “Today, we are seeing good demand for the higher purity ATBS... we are close to 100% utilization. Now, after the new line comes in place, again, it will take at least three years for it to achieve that full capacity utilization.”

    Confirms that the core ATBS business is back to full capacity, making the upcoming expansion critical for further growth.

    asked by Abhijit Akella, Kotak Securities

    2 min read5 chapters

    Detailed Narrative

    01

    ATBS Normalization and Expansion

    The ATBS segment, which accounts for 32% of total revenue, has successfully emerged from a global destocking phase. Management confirmed that existing capacity is currently running at nearly 100% utilization, particularly for high-purity grades. To meet future demand, an expansion is underway, though commissioning has been pushed to December 2024 or January 2025 due to equipment delivery delays from Europe. Once the new line is operational, it is expected to take approximately three years to reach full capacity utilization.

    02

    Antioxidant Business Facing Headwinds

    The antioxidant (AO) business contributed ₹130 crores in FY24, operating at a low 25% capacity utilization. The segment is currently facing significant price erosion and competitive pressure from Chinese manufacturers. Despite these challenges, management expects to scale up AO sales significantly in FY25, targeting at least 50% utilization as the global plastics market recovers. They remain confident in their long-term competitive edge due to their doubly backward-integrated manufacturing process.

    03

    VOPL Subsidiary and New Product Pipeline

    Vinati Organics is investing heavily in its 100% owned subsidiary, VOPL, with a total capex of approximately ₹500 crores. The subsidiary recently commissioned an MEHQ Guaiacol plant in March and expects to commission anisole, 4-methoxyacetophenone, and isoamylene derivatives in H2 FY25. Revenue from VOPL is projected to double from ₹130 crores to nearly ₹300 crores in the coming fiscal year, with a peak revenue potential of ₹500 crores achievable within three years.

    04

    Butyl Phenols and Anti-Dumping Benefits

    The Butyl Phenols segment was a key contributor in FY24, generating approximately ₹300 crores in revenue. Utilization improved from 65-70% for the full year to nearly 100% in the final quarter. Management noted that the imposition of anti-dumping duties has improved the pricing environment for butyl phenols. While revenue potential fluctuates with raw material prices, the segment is expected to continue delivering growth in FY25.

    05

    Strategic Shift to Solar Power

    As part of its operational efficiency and sustainability goals, the company has commissioned 33 megawatts of solar power capacity. This initiative is aimed at reducing dependence on conventional power sources and lowering overall energy costs. Management highlighted that these solar initiatives are already contributing to margin improvements by reducing power and fuel expenses.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.